Serum MOTS-c levels remain unchanged in patients with preeclampsia.

Tok A, Serdar O, Kandilcik OF, Alkan-Baylan F

Ginekologia polska1 Jan 2023Cited by 2 (Europe PMC)

PMID39469962DOI10.5603/gp.a2022.0095PepBankPUB-39469962

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
Serum levels of the body's own MOTS‑c did not differ between healthy pregnant women and women with mild or severe preeclampsia.
In plain wordsThe body's own MOTS‑c levels were similar in healthy pregnant women and in women with preeclampsia.
Peptide
MOTS-c
Outcome
No significant changeSerum MOTS-c in healthy, mild and severe preeclampsia
Study
n = 90
Comparator
Healthy pregnant controls
Outcome group
Mitochondrial function · Reproductive and sexual health
Measurements
MOTS-c level
159.1 ng/mL
healthy controls
MOTS-c level
129.6 ng/mL
mild preeclampsia
MOTS-c level
146.4 ng/mL
severe preeclampsia
Source sentences
Summary
Serum MOTS-c concentrations were statistically similar in healthy controls, mild and severe preeclampsia patients (159.1 ± 28.7 ng/mL vs 129.6 ± 54.7 ng/mL vs 146.4 ± 48.3, p = 0.166).
1 context sentence(design, population, supporting numbers)
Summary · context
This is cross sectional a case-control study of 30 patients with uncomplicated pregnancy, 30 patients with mild preeclampsia and 30 patients with severe preeclampsia that were admitted to the study center between June 2020 and January 2021.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3946996201
02HumanEndogenous levelObservational studyOther
Serum levels of the body's own MOTS‑c did not differ between healthy controls and women with early or late onset preeclampsia.
In plain wordsThe body's own MOTS‑c levels were similar in healthy pregnant women and in women with early or late onset preeclampsia.
Peptide
MOTS-c
Outcome
No significant changeSerum MOTS-c in early and late onset preeclampsia
Study
n: not reported in source
Comparator
Healthy pregnant controls
Outcome group
Mitochondrial function · Reproductive and sexual health
Measurements
MOTS-c level
159.1 ng/mL
healthy controls
MOTS-c level
126.7 ng/mL
early onset preeclampsia
MOTS-c level
153.7 ng/mL
late onset preeclampsia
Source sentences
Summary
Healthy controls and patients with early and late onset preeclampsia were statistically similar with respect to MOTS-c levels (159.1 ± 28.7 ng/mL vs 126.7 ± 56.9 vs 153.7 ± 39.8, p = 0.102).
1 context sentence(design, population, supporting numbers)
Summary · context
This is cross sectional a case-control study of 30 patients with uncomplicated pregnancy, 30 patients with mild preeclampsia and 30 patients with severe preeclampsia that were admitted to the study center between June 2020 and January 2021.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3946996202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.